Xenon Pharmaceuticals
XENE
290 hedge funds and large institutions have $5.8B invested in Xenon Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 81 funds opening new positions, 124 increasing their positions, 60 reducing their positions, and 33 closing their positions.
145% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 33
107% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 60
53% more capital invested
Capital invested by funds: $3.78B → $5.8B (+$2.02B)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
18% more funds holding
Funds holding: 246 → 290 (+44)
11.18% more ownership
Funds ownership: 109.29% → 120.48% (+11%)
8% less call options, than puts
Call options by funds: $127M | Put options by funds: $138M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$89.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$61.4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$59.9M |
| 5 |
DM
Deerfield Management
New York
|
+$49.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$44.9M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$34.1M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$22.4M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$20.3M |
| 5 |
Millennium Management
New York
|
-$20M |
XENE Hedge Fund Activity: Q1 2026 in Review
290 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2026, worth a combined $5.8B — up 53% from $3.78B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new XENE positions and 33 closed out — a net gain of 48 holders — while 124 added to existing stakes and 60 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $89.4M. The largest seller was Commodore Capital, cutting an estimated $44.9M.
- 290 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2026, up from 246 in Q4 2025.
- Funds reported $5.8B of Xenon Pharmaceuticals stock for Q1 2026, up 53% quarter-over-quarter.
- 81 funds opened new Xenon Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +48 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2026 was Polar Capital Holdings, an estimated $89.4M added.
- The largest Xenon Pharmaceuticals seller in Q1 2026 was Commodore Capital, an estimated $44.9M sold.
Based on aggregated 13F filings for Q1 2026.